Tag:

Enbrel

Latest Headlines

Latest Headlines

KKR steps in to back $55M C round for biosimilars developer Coherus

Just months after inking a $246 million development deal with Baxter for a biosimilar of Enbrel, Redwood City, CA-based Coherus has rounded up a whopping $55 million C round, including cash from KKR.

Kindred to scale back animal research

The company will reformulate drugs already approved for humans and market them for pets, and expects FDA approval for three drugs for dogs by the end of the year.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

Top 10 rheumatoid arthritis drugs 2013

Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...

Report: Seattle biotech VLST unloads assets and shuts doors

A 9-year run for VLST has ended. The Seattle biotech outfit has peddled assets to undisclosed buyers for undisclosed terms and shut its doors for good, Xconomy 's Luke Timmerman reported.

UPDATED: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown

Novartis says that one of its top Phase III drug prospects beat out Enbrel in a head-to-head showdown on psoriasis. Investigators say that the anti-IL17A secukinumab (AIN457) nabbed all the primary and secondary endpoints in the study.

Cheaper generic combo found as effective in RA as blockbuster Enbrel

Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.

Pfizer appealing CHMP ruling on RA treatment Xeljanz

Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.

Cipla steamrolls into Enbrel market with biosimilar of Amgen drug

While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid arthritis blockbuster Enbrel, which it will sell in the subcontinent at a 30% discount.

Star-crossed Merck reorganizes troubled biosimilars effort around Samsung pact

Just two months after Merck dropped out of a snake-bit biosimilar development program for Enbrel, the pharma giant--which has experienced a number of setbacks in the field--has stepped back up with a new, high-profile partnership, teaming up with a new venture formed by the South Korean conglomerate Samsung and Biogen Idec.